Barclays’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History

Barclays’s Portfolio BIOR Stock Details BIOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-601	Closed	-$3.02K	–	5597
2024 Q3	$3.02K	Buy	601 +21	+4%	+$136	﹤0.01%	5059
2024 Q2	$3.83K	Hold	580	–	–	﹤0.01%	4595
2024 Q1	$6.38K	Hold	580	–	–	﹤0.01%	4847
2023 Q4	$7.83K	Hold	580	–	–	﹤0.01%	4988
2023 Q3	$12.6K	Hold	580	–	–	﹤0.01%	4267
2023 Q2	$22.3K	Hold	580	–	–	﹤0.01%	4114
2023 Q1	$16.1K	Hold	580	–	–	﹤0.01%	4690
2022 Q4	$19.1K	Hold	580	–	–	﹤0.01%	4819
2022 Q3	$70K	Hold	580	–	–	﹤0.01%	3678
2022 Q2	$101K	Hold	580	–	–	﹤0.01%	3766
2022 Q1	$168K	Buy	+580	New	+$220K	﹤0.01%	3524

Barclays's BIOR Position: Q4 2024 in Review

Barclays sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q4 2024, closing a stake of 601 shares — an estimated $3.02K sold.

Barclays first reported a position in BIOR in Q1 2022 and held it in 11 quarters. The position peaked at $168K in Q1 2022. 0 funds tracked by Wall St. Rank hold BIOR as of Q4 2024.

Barclays reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Barclays sold 601 Biora Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $3.02K.
Barclays first reported a position in Biora Therapeutics, Inc. Common Stock in Q1 2022 and held it in 11 quarters.
Barclays's Biora Therapeutics, Inc. Common Stock position peaked at $168K in Q1 2022.
0 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Barclays's 13F filing for Q4 2024, filed 13 Feb 2025.